GlassScriptPhysician profile
Janice Hilley
NPI 1003232430
$1,563.47
in general payments reported to CMS, 2019-2025
34 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $339 · 2024: $511 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.48 |
| Education | $282.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $101.31 | 2023 | Jakafi, Pemazyre, Monjuvi |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Seagen INC. | $99.00 | 2025 | |
| Glaxosmithkline, LLC. | $97.80 | 2023 | Jemperli |
| Abbvie INC. | $86.97 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $86.91 | 2024-2025 | |
| Genzyme Corporation | $70.06 | 2023-2024 | |
| Genmab U.S., INC. | $67.93 | 2024-2025 | Epkinly |
| Pharmaessentia USA Corporation | $52.91 | 2024-2025 | Besremi |
| Pfizer INC. | $50.95 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $49.14 | 2023-2025 | Onivyde, Tazverik |
| Genentech USA, INC. | $46.64 | 2023-2025 | Tecentriq, Polivy |
| Celgene Corporation | $46.01 | 2023-2025 | Reblozyl |
| Astellas Pharma US INC | $43.42 | 2024-2025 | Vyloy, Padcev |
| Daiichi Sankyo INC. | $43.40 | 2024-2025 | Enhertu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.37 | 2023-2025 | |
| Exelixis INC. | $42.04 | 2024-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $39.88 | 2024-2025 | Ultomiris |
| Lilly USA, LLC | $39.87 | 2024-2025 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $36.85 | 2023-2025 | Libtayo |
| Puma Biotechnology, INC. | $33.83 | 2024-2025 | |
| Janssen Biotech, INC. | $33.60 | 2024 | Rybrevant |
| Beone Medicines USA, INC. | $27.16 | 2025 | Tevimbra |
| Stemline Therapeutics INC. | $26.38 | 2025 | Orserdu |
| Eisai INC. | $25.33 | 2025 | |
| Merck Sharp & Dohme LLC | $24.18 | 2025 | Welireg, Keytruda |
| Astrazeneca Pharmaceuticals LP | $21.01 | 2024 | |
| Adc Therapeutics America, INC. | $20.94 | 2025 | |
| Sobi, INC | $19.35 | 2025 | |
| Adaptive Biotechnologies Corporation | $19.02 | 2024 | Clonoseq |
| Amneal Pharmaceuticals LLC | $18.47 | 2025 | Alymsys |
| Iovance Biotherapeutics, INC. | $18.22 | 2025 | Amtagvi |
| E.R. Squibb & Sons, L.L.C. | $18.03 | 2023 | Opdivo |
| Tersera Therapeutics LLC | $15.49 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Hilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.